The clinical performance is complex and often involves multi-system congestion. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of interstitial brain tumours require individualized development, typically including multidimensional management, such as drug therapy, rehabilitation interventions, and regular follow-up visits. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of intermittent brain tumours. The platform serves a team of internationally authoritative experts in the field of blood tumours at home and abroad.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.